Sign In
Buy ALVR
$9.81
+0 (+0%)
At Close: Jun 17, 2025
Head to Head Review: AlloVir (NASDAQ:ALVR) versus SQZ Biotechnologies (NYSE:SQZ)
01:40am, Friday, 31'st Oct 2025
Valuation and Earnings This table compares SQZ Biotechnologies and AlloVir"s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/
ALLOVIR INVESTIGATION: Bragar Eagel & Squire, P.C. Continues Investigation into AlloVir, Inc. on Behalf of Long-Term Stockholders
05:14pm, Thursday, 16'th Oct 2025
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In AlloVir (ALVR) To Contact Him Directly To Discuss Their Options If you are a long-term s
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In AlloVir (ALVR) To Contact Him Directly To Discuss Their Options
Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Stockholders to Inquire about Securities Investigation
10:00am, Sunday, 15'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR)
NEW YORK, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR)
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR)
NEW YORK, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR).
Bronstein, Gewirtz & Grossman, LLC Is Investigating AlloVir Inc. (ALVR) And Encourages Stockholders to Connect
10:00am, Thursday, 05'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR).
Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities
08:00am, Thursday, 05'th Jun 2025
BOSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR).
Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Investors to Inquire about Securities Investigation
10:00am, Thursday, 29'th May 2025
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR).
Kalaris Announces Closing of Merger with AlloVir
04:21pm, Tuesday, 18'th Mar 2025
Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative dis
Kalaris and AlloVir Announce Stockholder Approval of Merger
04:01pm, Wednesday, 12'th Mar 2025
Combined company expected to trade on Nasdaq under “KLRS” after closing Combined company expected to trade on Nasdaq under “KLRS” after closing
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AlloVir, I
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR
10:12pm, Saturday, 09'th Nov 2024
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AlloVir, I
